What's Going On With Cel-Sci Shares Premarket On Monday?
What's Going On With Cel-Sci Shares Premarket On Monday?
The company plans to use proceeds to support the development of Multikine, general corporate purposes, and working capital.Cel-Sci Corporation (AMEX:CVM) shares are trading lower premarket on Monday.
周一，Cel-Sci Corporation（美国证券交易所股票代码：CVM）股票盘前交易价格走低。
On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.
周日，该公司披露了以每股0.31美元的价格公开发行1613万股普通股或预筹认股权证。
The company aims to raise around $5 million in gross proceeds. The offering is expected to close on December 31, 2024, subject to customary conditions.
该公司的目标是筹集约500万美元的总收益。此次发行预计将于2024年12月31日结束，但须遵守惯例条件。
The company plans to use proceeds to support the development of Multikine, general corporate purposes, and working capital.
该公司计划将所得款项用于支持Multikine的发展、一般公司用途和营运资金。
Earlier this month, CEL-SCI emphasized the strong biological rationale for using Multikine in its FDA-approved confirmatory registration study for head and neck cancer.
本月早些时候，CEL-SCI强调了在经美国食品药品管理局批准的头颈癌确认性注册研究中使用Multikine的强有力的生物学依据。
The study, involving 212 newly diagnosed patients with locally advanced, resectable head and neck cancer, will focus on those who demonstrated a 73% survival rate with Multikine compared to 45% for control patients in the prior Phase 3 trial.
该研究涉及212名新诊断的局部晚期可切除头颈癌患者，将重点关注Multikine的存活率为73％的患者，而在之前的3期试验中，对照组患者的存活率为45％。
Price Action: CVM shares are down 29.9% at $0.4204 premarket at the last check Monday.
价格走势：在周一的最后一次检查中，cVM股价下跌29.9％，至盘前0.4204美元。
- US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking
- 周五下跌后，美国股票期货下跌：“圣诞老人拉力赛” 存疑？分析师称其为有点获利回吐
Photo via Shutterstock.
照片来自 Shutterstock。
